Recent approaches by the PMDA to promoting new drug development: Change in the status of the PMDA in relation to new drug development over the last five years

Drug Information Journal

Volumn 43, Issue 1, 2009, Pages 47-55

  Mori, Kazuhiko ^a,b   Toyoshima, Satoshi ^a  

^a PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^b Japan Ministry of Health Labour and Welfare   (Japan)

Author keywords

Drug lag; Global development; Japan; Multinational clinical trial; Pharmaceuticals and Medical Devices Agency (PMDA)

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; ASIA; CLINICAL STUDY; CONSULTATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; EUROPE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; JAPAN; MEDICAL INFORMATION; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY CONTROL; REGENERATIVE MEDICINE; UNITED STATES;

EID: 59849107306     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300109     Document Type: Article

References (16)

1. Pharmaceuticals and Medical Devices Agency. About PMDA objective. Available at: http://www.pmda.go.jp/english/about/objective.html. Accessed May 1, 2008.
2. Ono S, Yoshioka C, Asaka O, Tamura K. The review of new drug applications in Japan: the decline in approval times after the introduction of an internalized review system. Drug Inf J. 2006; 39:279-290.
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: ethnic factors in the acceptability of foreign clinical data (E5(R1)), step 4. February 1998. Available at: http://www.ich.org/LOB/ media/MEDIA481.pdf. Accessed May 1, 2008.
4. Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38(2):80-86.
5. Uyama Y, Shibata T, Nagai N, Hanaoka H, Toyoshima S, Mori K. Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan. Clin Pharmacol Ther. 2005;78(2): 102-113.
6. Japanese Pharmaceutical Manufacturer Association Office of Pharmaceutical Industry Research. Research paper no. 31. May 2006. In Japanese. Available at: http://www.jpma.or.jp/opir/research/ paper-31.pdf. Accessed May 1, 2008.
7. The Interim Report of Clinical Trial Issue Review Committee. September 2006. Available at: http://www.pmda.go.jp/english/topics/pdf/ clinical.pdf. Accessed May 1, 2008.
8. ICH-E5: ethnic factors in the acceptability of foreign clinical data questions & answers (R1). June 2, 2006. Available at: http://www.ich.org/LOB/media/MEDIA1194.pdf. Accessed May 1, 2008.
9. Basic principles on global clinical trials. Informal translation by PMDA of Notification no. 09280710, Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministory of Health, Labor and Welfare. September 28, 2007. Available at: http://www.pmda.go.jp/operations/notice/2007/file/0928010-e.pdf. Accessed May 1, 2008.
10. Presentation by Young-Chan Kim (Korean FDA) at East Asian Pharmaceutical Regulatory Symposium 2008. Available at: http://www2.convention.co.jp/ eaprs2008ph/presen/0414-C-04.pdf. Accessed May 1, 2008.
11. Presentation by Herng-Der Chern (CDE Taiwan) at the fifth International Federation of Pharmaceutical Manufacturers Associations ARC 2008. Available at: http://www.ifpma.Org/arc-2008/uploads/media/ Chern_GDD_Breakout_2.pdf. Accessed May 1, 2008.
12. Presentation by Kazuhiko Mori (PMDA Japan) at the fifth IFPMA ARC 2008. Available at: http://www.ifpma.org/arc-2008/uploads/media/ Mori_GDD_Breakout_2.pdf. Accessed May 2, 2008.
13. Council for Science and Technology Policy. Institutional Reform for Promoting Science and Technology and Passing on the Benefits to Society. December 25, 2006. In Japanese. Available at: http://www8.cao.go.jp/cstp/ output/iken061225-1.pdf. Accessed May 2, 2008.
14. Pharmaceuticals and Medical Devices Agency. Actual operation results for FY2006. Annual Report FY2006. Available at: http://www.pmda.go.jp/ english/reports/pdf/2006/2title_FY2006.pdf. Accessed May 2, 2008.
15. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories E15, step 4. November 2007. Available at: http://www.ich.org/LOB/media/MEDIA3383.pdf. Accessed May 2, 2008.
16. East Asian Pharmaceutical Regulatory Symposium 2008. Tokyo, April 2008. Available at: http://www2.convention.co.jp/eaprs2008Ph/. Accessed May 2, 2008.